Vical hopes to proceed with Phase III CMV vaccine trial after positive advice from EMA
This article was originally published in Scrip
Vical, a US biopharmaceutical company, looks poised to move ahead with designing Phase III trials of its CMV (cytomegalovirus) vaccine, TransVax, after receiving positive scientific advice from the European Medicines Agency. The company is looking for a commercial partner for the vaccine in major markets in the Americas, Europe and Southeast Asia.
You may also be interested in...
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.